US venture capital (VC) in 3Q25 showed a measured recovery, with early-stage rounds proving resilient and late-stage funding more selective. Artificial Intelligence (AI) remained central to deal activity, but valuations...

Private market access in 401(k) plans is receiving greater interest, but the structure of these plans requires ongoing contributions and liquidity. Accordingly, initial adoption will emphasize income-oriented private assets, while...

Healthcare systems are emerging from a decade of disruption and reform. The pandemic was significant in exposing weaknesses in funding, capacity and operational resilience. Not only that, it also fast-paced...

Introduction: Reform as Market Signal Private equity thrives where markets balance growth with predictability. In India, that balance has often been clouded by regulatory complexity and uneven execution. Over the...

Capital is concentrating around AI-native SaaS platforms, while traditional players face sharper valuation discipline. Meanwhile, exit and funding activity reinforce investor confidence in enterprise innovation. Enterprise SaaS venture activity in...

Private equity firms are under pressure to deploy capital faster and exit with stronger returns. Deal cycles are shrinking, while the volume and complexity of data are expanding. Traditional approaches,...

Defense technology has moved from a niche frontier to a mainstream area of venture capital. Record funding levels, rising valuations, and stronger exits show that investors now view it as...

Public investors are rewarding profitability, sector alignment, and valuation discipline, not just top-line growth. The IPO window remains narrow, demanding stronger fundamentals and clearer exit strategies. After years of volatility,...

Cybersecurity VC held steady in 1Q25 as investor focus narrowed toward proven platforms and fast-scaling innovation. Sector resilience remained evident despite muted exits and thinning early-stage activity. Venture activity in...

Venture and private equity (PE) activity in medtech is rebounding after a multi-year lull, led by platform-driven innovation and disciplined capital deployment. Yet regulatory ambiguity and muted exit markets demand...